Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

NCT03052751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis

Interventions

DRUG: UCB7665
OTHER: Placebo

Sponsor

UCB Biopharma S.P.R.L.